TORONTO, Aug. 13, 2025 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to share insights on its US FDA site registration in relation to the possible rescheduling of cannabis in the United States.
Read more at newswire.ca
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
MediPharm Labs Positioned for Unique Opportunities on Possible Rescheduling of Cannabis in the United States
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
